Keywords: fda, rejects, merck, co, arcoxia, calls, additional

US FDA rejects Merck & Co's Arcoxia, calls for additional risk-benefit clinical data

Article | 07 May 2007

Print This

The US Food and Drug Administration has rejected drug major Merck & Co's controversial drug for the symptoms of osteoathritis Arcoxia ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in